Quinto Resources Inc. ("Quinto") (TSXV: QIT) and Emerald Health
Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) have
entered into a share purchase agreement dated July 30, 2020 (the
"Agreement") in respect of the sale of Emerald's wholly-owned
subsidiaries, Verdélite Sciences, Inc. (“Verdélite Sciences”) and
Verdélite Property Holdings, Inc. (“Verdélite Property” and,
together with Verdélite Sciences, the “Subsidiaries”). The
Subsidiaries together own and operate a premium 88,000 square foot
craft cannabis production indoor facility (the “Facility”) in St.
Eustache, Québec.
Pursuant to the Agreement, Quinto will purchase
all of the issued and outstanding shares of the Subsidiaries in
consideration for a cash purchase price of $21,000,000 (the
“Purchase Price”), plus the aggregate amount of cash of each of the
Subsidiaries at the closing date less the amount of long-term debts
of each of the Subsidiaries as at the closing date, subject to a
post-closing working capital adjustment (the "Transaction").The
Agreement was negotiated at arm's-length. Closing of the
Transaction is anticipated to occur on or before August 31,
2020, subject to the TSX Venture Exchange’s (the “TSXV”)
approval.
As a result of the Transaction, the Subsidiaries
will become wholly-owned subsidiaries of Quinto and Quinto will
continue the business of the Subsidiaries. Following closing of the
Transaction, Emerald will continue to sell its own products into
the Québec market, subject to certain limited restrictions, and
retains exclusive rights to its recently launched SouvenirTM
brand.
Since Quinto is a Canadian public company with
its common shares listed for trading on the TSXV, the Transaction
will constitute a change of business for Quinto under the rules of
the TSXV – please see "The Transaction", below. As a result, Quinto
will require the approval of its shareholders to complete the
Transaction and will call a shareholder meeting, subject to the
TSXV approval.
The Subsidiaries
Verdélite Sciences is a company incorporated
under the Canada Business Corporations Act. Verdélite Sciences
became a licensed producer on January 12, 2018. Verdélite Property
is a company incorporated under the Québec Business Corporations
Act, which acquired the Facility on February 9, 2017. On May 1,
2018, Emerald acquired 100% of the issued and outstanding shares of
the Subsidiaries from the founding group.
Verdélite Sciences holds a standard processing
licence from Health Canada with respect to the complete growing and
processing area at the Facility permitting it to sell and
distribute packaged, branded dried cannabis products directly to
provincial/territorial wholesalers and authorized private
retailers. Cultivation commenced at the Facility in late 2019 and
the Facility is now in full production.
According to the combined unaudited financial
statements of the Subsidiaries for the financial year ended
December 31, 2019, the total assets were $26,324,162, the total
liabilities were $37,848,924, the revenues were $4,131,533 and the
net loss was $11,000,110.
The Agreement
Pursuant to the Agreement, Quinto will purchase
all of the issued and outstanding shares of the Subsidiaries at
closing in consideration for a cash purchase price of $21,000,000.
The Purchase Price will be adjusted at closing for cash and
long-term debt of the Subsidiaries and post-closing for working
capital of the Subsidiaries as at closing above or below a target
amount. The Purchase Price will be subject to a $750,000 holdback
for the working capital adjustment and as an indemnity for certain
pre-existing litigation. The Agreement contains representations and
warranties, covenants, conditions and indemnities for the benefit
of each of the parties as are customary for transactions of this
nature. A copy of the Agreement will be posted on the parties’
respective profiles at www.sedar.com.
The Transaction
The Transaction, if completed, will constitute a
“Change of Business” of Quinto pursuant to Policy 5.2 – Changes of
Business and Reverse Takeovers of the TSXV. Trading in the common
shares of Quinto is halted as a result of this announcement and
will remain halted until the resumption of trading is approved by
the TSXV.
Quinto expects to finance the acquisition
through a combination of private placements and bridge financing,
including two debt bridge financings of approximately five million
dollars each, a brokered private placement of approximately twelve
million dollars, (subject to market conditions and due diligence
being completed by the financiers) and a five million dollar
financing from the original founders group of the Subsidiaries, who
sold the Subsidiaries to Emerald in 2018. The founder group
financing is expected to be satisfied by the assignment of an
equivalent amount of debt owed by Emerald to such persons. The
parties intend to offset such assigned debt against a portion of
the Purchase Price.
Quinto will use the net proceeds from such
financings to pay the Purchase Price (including the assignment of
debt referred to above) and, as applicable, the adjustments, if
any, and for general working capital purposes.
Quinto will pay commissions and finders fees in
connection with such financings. The percentage of such commissions
and fees are not known at this time, but they will be determined in
accordance with limits prescribed by TSXV’s policies.
Quinto expects to retain the services of Haywood
Securities Inc. to act as sponsor in connection with the
Transaction, but the terms and conditions of the sponsorship have
not yet been determined. An agreement to sponsor should not be
construed as any assurance with respect to the merits of the
Transaction or the likelihood of completion.
Principals and Insiders
Pursuant to the closing of the Transaction the
following persons will constitute the principals and insiders of
Quinto: Philippe Frère, Marcel Bergeron and Michael Curtis.
Management of Quinto will propose the election of two additional
directors who will both be independent in order to create a
five-person Board of Directors. Mr. Frère is the current Chairman
of the Board of Directors of Quinto and has been director of Quinto
since 2010. He is a partner and Chairman of the Board of Directors
of Lavery, de Billy, L.L.P., a Québec based law firm. Mr. Bergeron
has been Chief Financial Officer and director of Quinto since 2010.
He is a member of the Ordre des comptables professionnels agréés du
Québec and he has an extensive experience in the Canadian financial
industry. Mr. Curtis has been President, Chief Executive Officer
and director of Quinto until 2019. He has 35 years of experience in
the Canadian financial industry in the areas of trading, research,
corporate finance and the management of public companies.
A further press release will be disseminated
upon closing of the Transaction in accordance with the policies of
the TSXV.
About Quinto Resources Inc.
Quinto Resources Inc. (TSX-V: QIT) is a Canadian
gold exploration Corporation. It owns a 2.5% interest in the
Monster Lake property (IAMGOLD: 75%/TomaGold: 22.5%) in Québec,
Canada.
Please visit www.quintocorp.com for more information or
contact:
Marcel BergeronChief Financial
Officer
(514) 232-3344marcel.bergeron1@videotron.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. The TSX Venture Exchange
Inc. has in no way passed upon the merits of the proposed
Transaction and has neither approved nor disapproved the contents
of this news release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include: the completion of the Transaction and the timing thereof.
Completion of the Transaction is subject to a number of conditions,
including but not limited to, TSXV acceptance and if applicable,
disinterested shareholder approval. Where applicable, the
Transaction cannot close until the required shareholder approval is
obtained. There can be no assurance that the Transaction will be
completed as proposed or at all.
Investors are cautioned that, except as
disclosed in the management information circular to be prepared in
connection with the Transaction, any information released or
received with respect to the Transaction may not be accurate or
complete and should not be relied upon. Trading in the securities
of Quinto should be considered highly speculative.
We cannot guarantee that any forward-looking
statement herein will materialize, and readers are cautioned not to
place undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, changes of law and regulations; changes of
government; failure to obtain regulatory approvals or Quinto
shareholder approval; failure of Quinto to obtain necessary
financing; failure to obtain third party consents; results of
production and sale activities; regulatory changes; changes in
prices and costs of inputs; demand for products; failure of
counter-parties to perform contractual obligations; as well as the
risk factors described in Emerald’s annual information form and
other regulatory filings. The forward-looking statements contained
in this press release represent our expectations as of the date
hereof. Forward-looking statements are presented for the purpose of
providing information about management's current expectations and
plans and allowing investors and others to obtain a better
understanding of our anticipated operating environment. Readers are
cautioned that such information may not be appropriate for other
purposes.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Nov 2023 to Nov 2024